Stock PIQ PROTEOMICS INTERNATIONAL LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Proteomics International Laboratories Limited

Equities

PIQ

AU000000PIQ0

Market Closed - Australian S.E.
Other stock markets
 01:22:03 2024-04-26 am EDT 		5-day change 1st Jan Change
1.095 AUD +0.46% Intraday chart for Proteomics International Laboratories Limited +0.46% +22.35%
Mar. 25 Proteomics International Signs Agreement with University of Oxford for Endometriosis Study MT
Mar. 19 Proteomics Says PromarkerD's US Launch Delayed MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PROTEOMICS INTERNATIONAL LABORATORIES LIMITED Stock Proteomics International Laboratories Limited
+22.35% 93.47M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
B+
ARGENX SE Stock argenx SE
+1.69% 22.15B
B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
B+
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PIQ Stock
  4. Ratings Proteomics International Laboratories Limited